YTEN - Yield10 Bioscience Inc Stock Price, Fair Value and News

0.23USD-0.01 (-4.17%)Delayed

Market Summary

USD0.23-0.01

Delayed

-4.17%

YTEN Stock Price

View Fullscreen

YTEN RSI Chart

YTEN Valuation

Market Cap

3.5M

Price/Earnings (Trailing)

-0.25

Price/Sales (Trailing)

59.04

EV/EBITDA

-0.16

Price/Free Cashflow

-0.35

YTEN Price/Sales (Trailing)

YTEN Profitability

EBT Margin

-24091.67%

Return on Equity

582.16%

Return on Assets

-369.98%

Free Cashflow Yield

-285.51%

YTEN Fundamentals

YTEN Revenue

Revenue (TTM)

60.0K

Rev. Growth (Yr)

-100%

YTEN Earnings

Earnings (TTM)

-14.5M

Earnings Growth (Yr)

1.12%

Earnings Growth (Qtr)

12.35%

Breaking Down YTEN Revenue

Last 7 days

-11.5%

Last 30 days

-39.5%

Last 90 days

4.6%

Trailing 12 Months

-92.0%

How does YTEN drawdown profile look like?

YTEN Financial Health

Current Ratio

0.29

YTEN Investor Care

Shares Dilution (1Y)

203.27%

Diluted EPS (TTM)

-1.88

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	361.0K	258.0K	147.0K	60.0K
2022	567.0K	496.0K	515.0K	450.0K
2021	816.0K	769.0K	657.0K	614.0K
2020	861.0K	764.0K	744.0K	799.0K
2019	620.0K	653.0K	801.0K	806.0K
2018	680.0K	672.0K	525.0K	556.0K
2017	1.3M	1.4M	1.2M	944.0K
2016	1.7M	1.2M	1.3M	1.2M
2015	2.8M	2.9M	2.6M	2.2M
2014	3.1M	2.7M	2.7M	2.8M
2013	3.3M	3.5M	3.5M	3.8M
2012	17.2M	25.3M	33.3M	41.4M
2011	594.0K	676.0K	1.1M	9.2M
2010	0	1.1M	773.7K	448.0K
2009	0	0	0	1.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Yield10 Bioscience Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 28, 2024	sinskey anthony j	acquired	-	-	20,561	-
Mar 28, 2024	hamilton richard william	acquired	-	-	41,118	-
Mar 28, 2024	van nostrand robert l	acquired	-	-	11,924	-
Feb 15, 2024	peoples oliver p	acquired	60,000	0.3	200,000	president and ceo
Feb 15, 2024	snell kristi	acquired	36,000	0.3	120,000	vp research and cso
Feb 15, 2024	brum lynne h	acquired	30,000	0.3	100,000	vp, planning and corporate com
Feb 15, 2024	haaser charles b	acquired	30,000	0.3	100,000	vp finance and cao
Dec 29, 2023	hamilton richard william	acquired	-	-	16,275	-
Dec 29, 2023	van nostrand robert l	acquired	-	-	18,879	-
Dec 29, 2023	sinskey anthony j	acquired	-	-	16,275	-

Which funds bought or sold YTEN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Ulland Investment Advisors, LLC	new	-	-	-	-%
Apr 11, 2024	SALEM INVESTMENT COUNSELORS INC	unchanged	-	-	1.00	-%
Mar 11, 2024	VANGUARD GROUP INC	unchanged	-	-3,535	9,680	-%
Mar 04, 2024	VIMA LLC	new	-	3.00	3.00	-%
Feb 26, 2024	Virtu Financial LLC	added	135	4,000	9,000	-%
Feb 14, 2024	TWO SIGMA SECURITIES, LLC	sold off	-100	-3,989	-	-%
Feb 14, 2024	MILLENNIUM MANAGEMENT LLC	reduced	-40.77	-10,199	7,856	-%
Feb 14, 2024	CITADEL ADVISORS LLC	reduced	-61.99	-6,254	2,424	-%
Feb 13, 2024	BlackRock Inc.	unchanged	-	-2,742	7,510	-%
Feb 13, 2024	MORGAN STANLEY	sold off	-100	-	-	-%

Are Funds Buying or Selling YTEN?

Are funds buying YTEN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own YTEN

No. of Funds

Unveiling Yield10 Bioscience Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Oct 11, 2023	schuler jack w	21.8%	2,835,339	SC 13D
May 26, 2023	schuler jack w	21.7%	1,395,339	SC 13D/A
Apr 08, 2022	hirschman orin	0%	0	SC 13G/A
Feb 11, 2022	hirschman orin	7.15%	349,200	SC 13G/A
Feb 04, 2022	hudson bay capital management lp	0.20%	10,000	SC 13G/A
Jun 09, 2021	morgan stanley	2.0%	96,095	SC 13G/A
Feb 11, 2021	hudson bay capital management lp	6.65%	237,500	SC 13G
Feb 05, 2021	schuler jack w	37.69%	1,735,443	SC 13D/A
Feb 01, 2021	morgan stanley	5.1%	169,627	SC 13G
Jan 19, 2021	lind global macro fund lp	4.5%	150,678	SC 13G/A

Recent SEC filings of Yield10 Bioscience Inc

View All Filings

Date Filed	Form Type	Document
Apr 25, 2024	S-1	Initial Public Offering
Apr 19, 2024	PRE 14A	PRE 14A
Apr 04, 2024	DEF 14A	DEF 14A
Apr 02, 2024	PRE 14A	PRE 14A
Apr 01, 2024	10-K	Annual Report
Apr 01, 2024	4	Insider Trading
Apr 01, 2024	4	Insider Trading
Apr 01, 2024	4	Insider Trading
Apr 01, 2024	8-K	Current Report
Mar 29, 2024	8-K	Current Report

Peers (Alternatives to Yield10 Bioscience Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
CTVA	38.5B	17.2B	-3.65%	-9.48%	52.19	2.24	-1.31%	-35.78%
CF	15.1B	6.6B	-3.17%	14.09%	8.2	2.27	-40.72%	-53.31%
MOS	9.7B	13.7B	-5.59%	-28.18%	8.35	0.71	-28.39%	-67.49%
MID-CAP
FMC	7.3B	4.5B	-6.81%	-52.02%	5.52	1.62	-22.67%	79.43%
SMG	3.8B	3.4B	-7.96%	2.36%	-9.7	1.12	-11.57%	12.45%
SMALL-CAP
UAN	865.9M	681.5M	6.82%	-7.85%	5.02	1.27	-18.44%	-39.88%
AVD	330.3M	579.4M	-9.33%	-39.15%	43.93	0.57	-4.96%	-72.56%
IPI	256.8M	174.0M	-4.22%	-23.13%	-7.2	1.71	2.45%	-149.39%
CGA	42.6M	119.8M	3.36%	-5.81%	-2.61	0.33	-26.60%	70.57%
YTEN	3.5M	60.0K	-39.47%	-91.99%	-0.25	59.04	-86.67%	-6.55%

Yield10 Bioscience Inc News

Latest updates

Yield10 Bioscience Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-	-	-	-	60,000	87,000	111,000	103,000	149,000	152,000	92,000	174,000	196,000	195,000	204,000	221,000	179,000	140,000	224,000	318,000	124,000	135,000
Costs and Expenses	-12.3%	3,247,000	3,703,000	3,667,000	3,860,000	3,291,000	3,601,000	3,539,000	3,470,000	3,120,000	3,183,000	3,255,000	2,748,000	2,805,000	2,398,000	2,358,000	2,847,000	2,555,000	2,222,000	2,216,000	2,409,000	2,030,000
S&GA Expenses	-14.1%	1,287,000	1,499,000	1,670,000	1,698,000	1,403,000	1,518,000	1,523,000	1,707,000	1,522,000	1,547,000	1,604,000	1,432,000	1,383,000	1,098,000	1,179,000	1,387,000	1,353,000	990,000	1,025,000	1,186,000	943,000
EBITDA Margin	-146.7%	-236	-95.71	-53.59	-37.64	-29.19	-25.13	-23.93	-20.34	-17.53	-15.86	-13.26	-10.93	-12.47	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	129,000	9,000	9,000	9,000	11,000	6,000	11,000	8,000	30,000	11,000	7,000	8,000	-254,000	-	-	-	-
Earnings Before Taxes	12.3%	-3,266,000	-3,726,000	-3,681,000	-3,782,000	-3,174,000	-3,480,000	-3,434,000	-3,322,000	-2,969,000	-2,392,000	-3,081,000	-2,553,000	-2,612,000	-2,157,000	-1,789,000	-3,592,000	-7,097,000	-1,982,000	-1,871,000	-2,260,000	-
EBT Margin	-146.6%	-240	-97.71	-54.72	-38.42	-29.80	-25.64	-24.43	-20.75	-17.91	-16.19	-13.53	-11.17	-12.70	-	-	-	-	-	-	-	-
Net Income	12.3%	-3,266,000	-3,726,000	-3,681,000	-3,782,000	-3,303,000	-3,489,000	-3,443,000	-3,331,000	-2,980,000	-2,398,000	-3,092,000	-2,561,000	-2,642,000	-2,168,000	-1,796,000	-3,600,000	-6,843,000	-1,982,000	-1,871,000	-2,260,000	-1,862,000
Net Income Margin	-144.4%	-240	-98.59	-55.25	-38.83	-30.15	-25.71	-24.50	-20.81	-17.97	-16.28	-13.61	-11.23	-12.77	-	-	-	-	-	-	-	-
Free Cashflow	33.7%	-1,731,000	-2,610,000	-3,097,000	-2,676,000	-3,062,000	-2,723,000	-2,557,000	-3,216,000	-2,527,000	-2,003,000	-2,174,000	-2,738,000	-2,023,000	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-35.3%	3,907	6,042	5,870	5,334	8,085	11,272	14,273	17,104	20,415	22,946	25,210	27,568	14,522	16,646	13,366	15,046	16,718	9,419	11,156	13,095	12,960
Current Assets	-58.4%	1,400	3,362	3,025	2,443	5,018	7,895	10,704	13,375	16,624	19,054	21,185	22,530	10,342	12,361	8,990	10,509	11,684	3,499	5,017	6,738	6,377
Cash Equivalents	-52.7%	1,332	2,817	2,336	1,809	2,356	4,186	3,444	2,392	5,593	14,882	15,905	18,846	3,687	3,249	3,544	4,549	5,749	3,209	3,584	6,397	3,355
Net PPE	-7.7%	548	594	663	715	775	840	895	945	890	903	949	968	921	935	978	1,021	1,243	1,247	1,298	1,335	1,385
Liabilities	13.1%	6,390	5,650	5,283	4,191	3,685	4,052	4,002	3,893	4,389	4,458	4,748	4,474	4,990	4,774	4,879	5,717	20,803	6,799	6,702	6,900	7,262
Current Liabilities	23.1%	4,865	3,953	2,470	2,270	1,610	1,826	1,627	1,376	1,733	1,666	1,823	1,421	1,814	1,476	1,462	2,187	2,207	1,754	1,506	1,502	1,641
Shareholder's Equity	-733.4%	-2,483	392	587	1,143	4,400	7,220	10,271	13,211	16,026	18,488	20,462	23,094	9,532	11,872	8,487	9,329	-	2,620	4,454	6,195	5,698
Retained Earnings	-0.8%	-414,152	-410,886	-407,160	-403,479	-399,697	-396,394	-392,905	-389,462	-386,131	-383,151	-380,753	-377,661	-375,100	-372,458	-370,290	-368,494	-364,894	-358,051	-356,069	-354,198	-351,938
Additional Paid-In Capital	0.1%	411,814	411,406	407,930	404,803	404,277	403,799	403,347	402,817	402,283	401,760	401,319	400,865	384,758	384,465	378,924	377,963	360,926	360,670	360,516	360,383	357,743
Shares Outstanding	1.1%	12,032	11,902	6,100	5,079	4,944	4,925	4,900	4,889	4,882	4,681	4,584	4,296	3,334	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	-	8,868	-	-	-	33,637	-	-	-	9,581	-	-	-	8,012	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	34.5%	-1,711	-2,611	-3,079	-2,667	-3,062	-2,702	-2,538	-3,102	-2,485	-1,992	-2,139	-2,637	-1,989	-2,058	-2,324	-2,288	-3,209	-1,368	-1,781	-2,296	-2,023
Share Based Compensation	1.1%	383	379	394	436	445	447	488	523	500	436	415	324	233	209	160	137	250	131	113	162	229
Cashflow From Investing	-2100.0%	-20.00	1.00	-18.00	1,982	1,500	3,494	3,616	-88.00	-6,807	1,006	-807	2,030	2,480	-3,589	249	215	-5,749	999	-1,011	2,746	1,746
Cashflow From Financing	-100.0%	-	3,092	3,638	141	-	-23.00	-	-14.00	-	-20.00	-	15,766	-62.00	5,350	1,063	928	11,500	-	-18.00	2,597	-

YTEN Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue:
Total revenue	$ 60	$ 450
Expenses:
Research and development	8,323	7,750
General and administrative	6,154	6,151
Total expenses	14,477	13,901
Loss from operations	(14,417)	(13,451)
Other income (expense):
Other income (expense), net	(38)	41
Total other income (expense)	(38)	41
Loss from operations before income taxes	(14,455)	(13,410)
Income tax provision	0	(156)
Net loss	$ (14,455)	$ (13,566)
Basic net loss per share (in dollars per share)	$ (1.82)	$ (2.76)
Diluted net loss per share (in dollars per share)	$ (1.82)	$ (2.76)
Number of shares used in per share calculations:
Basic (in shares)	7,946,281	4,914,565
Diluted (in shares)	7,946,281	4,914,565

YTEN Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current Assets:
Cash and cash equivalents	$ 1,068	$ 2,356
Short-term investments	0	1,991
Unbilled receivables	0	30
Prepaid expenses and other current assets	332	641
Total current assets	1,400	5,018
Restricted cash	264	264
Property and equipment, net	548	775
Right-of-use assets	1,653	1,961
Other assets	42	67
Total assets	3,907	8,085
Current Liabilities:
Accounts payable	1,202	109
Accrued expenses	2,010	926
Lease liabilities	669	575
Convertible note payable, net of issuance costs (Note12)	984	0
Total current liabilities	4,865	1,610
Lease liabilities, net of current portion	1,525	2,075
Total liabilities	6,390	3,685
Commitments and contingencies (Note 7)
Stockholders' Equity (Deficit):
Preferred stock ($0.01 par value per share); 5,000,000 shares authorized; no shares issued or outstanding	0	0
Common stock ($0.01 par value per share); 60,000,000 shares authorized at December 31, 2023 and 2022, and 12,032,425 and 4,944,202 shares issued and outstanding at December 31, 2023 and 2022, respectively	120	49
Additional paid-in capital	411,814	404,277
Accumulated other comprehensive loss	(265)	(229)
Accumulated deficit	(414,152)	(399,697)
Total stockholders' equity (deficit)	(2,483)	4,400
Total liabilities and stockholders' equity (deficit)	$ 3,907	$ 8,085

About Yield10 Bioscience Inc

Yield10 Bioscience, Inc. operates as agricultural bioscience company in the United States. The company primarily focus on production of low carbon products through processing Camelina seeds. Its products include Camelina oil for low carbon biofuel feedstock; Omega-3 oils for nutrition; and PHA bioplastics for biodegradable zero waste packaging solutions. The company was formerly known as Metabolix, Inc. and changed its name to Yield10 Bioscience, Inc. in January 2017. Yield10 Bioscience, Inc. was incorporated in 1992 and is headquartered in Woburn, Massachusetts.

CEO	Dr. Oliver P. Peoples Ph.D.
WEBSITE	yield10bio.com
INDUSTRY	Agriculture
EMPLOYEES	30

Yield10 Bioscience Inc Frequently Asked Questions

What is the ticker symbol for Yield10 Bioscience Inc? What does YTEN stand for in stocks?

YTEN is the stock ticker symbol of Yield10 Bioscience Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Yield10 Bioscience Inc (YTEN)?

As of Fri Apr 26 2024, market cap of Yield10 Bioscience Inc is 3.54 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of YTEN stock?

You can check YTEN's fair value in chart for subscribers.

What is the fair value of YTEN stock?

You can check YTEN's fair value in chart for subscribers. The fair value of Yield10 Bioscience Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Yield10 Bioscience Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for YTEN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Yield10 Bioscience Inc a good stock to buy?

The fair value guage provides a quick view whether YTEN is over valued or under valued. Whether Yield10 Bioscience Inc is cheap or expensive depends on the assumptions which impact Yield10 Bioscience Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for YTEN.

What is Yield10 Bioscience Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, YTEN's PE ratio (Price to Earnings) is -0.25 and Price to Sales (PS) ratio is 59.04. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. YTEN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Yield10 Bioscience Inc's stock?

In the past 10 years, Yield10 Bioscience Inc has provided -0.606 (multiply by 100 for percentage) rate of return.